J Listing

Summary

Affiliation: German Rheumatism Research Centre
Country: Germany

Publications

  1. doi request reprint The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
    Joachim Listing
    German Rheumatism Research Centre Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Rheumatology (Oxford) 52:53-61. 2013
  2. pmc Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
  3. pmc Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
    Anja Strangfeld
    German Rheumatism Research Centre Berlin, a Leibniz Institute, Chariteplatz 1, 10117 Berlin, Germany
    Arthritis Res Ther 12:R5. 2010
  4. doi request reprint Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Joachim Listing
    German Rheumatism Research Centre, Berlin, Germany
    Arthritis Rheum 58:667-77. 2008
  5. pmc Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register
    Joachim Listing
    German Rheumatism Research Centre, Berlin, Germany
    Arthritis Res Ther 8:R66. 2006
  6. ncbi request reprint Infections in patients with rheumatoid arthritis treated with biologic agents
    Joachim Listing
    German Rheumatism Research Centre, Schumannstrasse 21 22, D 10117 Berlin, Germany
    Arthritis Rheum 52:3403-12. 2005
  7. pmc Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
  8. pmc Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
  9. ncbi request reprint [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
    H Haibel
    Deutsches Rheuma ForschungsZentrum, Berlin
    Z Rheumatol 63:393-401. 2004
  10. ncbi request reprint Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, Charite Medical School, Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005

Detail Information

Publications55

  1. doi request reprint The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
    Joachim Listing
    German Rheumatism Research Centre Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Rheumatology (Oxford) 52:53-61. 2013
    ..This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions...
  2. pmc Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
    ..Therefore, we analysed parameters of cartilage degradation, neoangiogenesis, and new bone formation in different cohorts of patients with axial spondyloarthritis with and without treatment with TNF-alpha blocker agents...
  3. pmc Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
    Anja Strangfeld
    German Rheumatism Research Centre Berlin, a Leibniz Institute, Chariteplatz 1, 10117 Berlin, Germany
    Arthritis Res Ther 12:R5. 2010
    ....
  4. doi request reprint Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Joachim Listing
    German Rheumatism Research Centre, Berlin, Germany
    Arthritis Rheum 58:667-77. 2008
    ..To determine the hazard risk of developing or worsening heart failure in rheumatoid arthritis (RA) patients treated with tumor necrosis factor alpha (TNFalpha) inhibitors...
  5. pmc Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register
    Joachim Listing
    German Rheumatism Research Centre, Berlin, Germany
    Arthritis Res Ther 8:R66. 2006
    ..However, temporary or even sustained remission remain ambitious aims, which are achieved in a minority of patients only...
  6. ncbi request reprint Infections in patients with rheumatoid arthritis treated with biologic agents
    Joachim Listing
    German Rheumatism Research Centre, Schumannstrasse 21 22, D 10117 Berlin, Germany
    Arthritis Rheum 52:3403-12. 2005
    ....
  7. pmc Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
    ..To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS)...
  8. pmc Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
    ..TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS)...
  9. ncbi request reprint [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
    H Haibel
    Deutsches Rheuma ForschungsZentrum, Berlin
    Z Rheumatol 63:393-401. 2004
    ..Furthermore the data can be compared to the German standard population...
  10. ncbi request reprint Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, Charite Medical School, Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005
    ..It is not known whether spinal inflammation remains suppressed over time. Our objective was to assess spinal inflammation by MRI in AS patients after 2 yr of continuous infliximab treatment...
  11. doi request reprint The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:770-6. 2009
    ..The objective of this study was to develop candidate classification criteria for axial SpA that include patients with but also without radiographic sacroiliitis...
  12. ncbi request reprint Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    J Brandt
    Benjamin Franklin Hospital, Free University Berlin, Berlin, Germany
    Arthritis Rheum 48:1667-75. 2003
    ..This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fusion protein, in active AS...
  13. ncbi request reprint Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
    J Braun
    Benjamin Franklin Hospital, Free University, Berlin, Germany
    Arthritis Rheum 48:2224-33. 2003
    ..The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1-year period...
  14. pmc Treatment continuation in patients receiving biological agents or conventional DMARD therapy
    A Zink
    German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 64:1274-9. 2005
    ....
  15. ncbi request reprint The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database
    K Minden
    German Rheumatism Research Centre, Berlin, Germany
    Clin Exp Rheumatol 27:863-9. 2009
    ..To estimate the cost of juvenile idiopathic arthritis (JIA) and to evaluate the influence of specific disease characteristics on the various costs domains...
  16. ncbi request reprint Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Clin Exp Rheumatol 26:247-52. 2008
    ..The aim of this study was to prospectively investigate the therapeutic efficacy and safety of infliximab therapy in NSAID-refractory AS patients, with special emphasis on impact on quality of life in daily practice...
  17. pmc The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis
    A Zink
    Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 60:207-13. 2001
    ..To describe current treatment of patients with rheumatoid arthritis (RA) in German rheumatology...
  18. doi request reprint Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide
    A Strangfeld
    German Rheumatism Research Centre, Epidemiology Unit, 10117 Berlin, Germany
    Ann Rheum Dis 68:1856-62. 2009
    ....
  19. pmc Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 70:1257-63. 2011
    ....
  20. pmc Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
    M Rudwaleit
    Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 61:968-74. 2002
    ..The prevalence of atopic disorders in ankylosing spondylitis (AS) is unknown. AS and rheumatoid arthritis (RA) exhibit divergent T helper (Th) cell cytokine patterns...
  21. pmc Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
    A Strangfeld
    Correspondence to Dr A Strangfeld, Programmbereich Epidemiologie, Deutsches Rheuma ForschungsZentrum Berlin, ein Leibniz Institut, Chariteplatz 1, 10117 Berlin, Germany
    Ann Rheum Dis 70:1914-20. 2011
    ..To examine the risk of serious infection conveyed by tumour necrosis factor α (TNFα) inhibitors in the treatment of rheumatoid arthritis (RA)...
  22. pmc Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    M Rudwaleit
    Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 64:1305-10. 2005
    ....
  23. pmc Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
    ..To develop and compare candidate improvement criteria for anti-TNFalpha treatment in ankylosing spondylitis with optimal discriminating capacity between treatment and placebo...
  24. doi request reprint Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial
    I H Song
    Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 62:1290-7. 2010
    ....
  25. doi request reprint Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:1701-7. 2009
    ....
  26. ncbi request reprint [Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis]
    G Westhoff
    Deutsches Rheuma ForschungsZentrum Berlin, Forschungsbereich Epidemiologie, Schumannstrasse 21 22, 10117 Berlin, Germany
    Z Rheumatol 63:414-24. 2004
    ..As policymakers discuss cost sharing and design of benefit packages to contain health spending, it is important to consider the expenditures that persons with chronic conditions like rheumatoid arthritis already have...
  27. doi request reprint The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:777-83. 2009
    ..To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA)...
  28. pmc The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients
    A Zink
    Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 60:199-206. 2001
    ..To describe the aims, principles, and content of the German rheumatological database and to present data on patient mix and healthcare provision for the year 1998...
  29. ncbi request reprint Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres
    A Zink
    Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
    Lupus 13:529-36. 2004
    ..The great disparity in treatment intensity between rheumatologists and nonrheumatologists shows that the involvement of a specialist is needed equally in both diseases...
  30. ncbi request reprint Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    J Braun
    Department of Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Berlin, Germany
    Lancet 359:1187-93. 2002
    ..BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients...
  31. doi request reprint [Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research]
    T Haupl
    Medizinische Klinik m S Rheumatologie und Klinische Immunologie, Charite Universitatsmedizin Berlin, Campus Mitte, Chariteplatz 1, 10117, Berlin, Deutschland
    Z Rheumatol 71:314-8. 2012
    ..To validate the markers for diagnostic application the network aims to expand gradually...
  32. ncbi request reprint Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers
    A Zink
    German Rheumatism Research Center, Department of Internal Medicine, Klinikum Benjamin Franklin, Berlin, Free University
    J Rheumatol 27:613-22. 2000
    ....
  33. ncbi request reprint Practice variation in the treatment of rheumatoid arthritis among German rheumatologists
    A Zink
    Epidemiology Unit, German Rheumatism Research Center, Berlin
    J Rheumatol 28:2201-8. 2001
    ..To describe practice variation in the treatment of rheumatoid arthritis (RA) among German rheumatologists with regard to drug and non-drug therapy...
  34. ncbi request reprint [Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT]
    A Zink
    Forschungsbereich Epidemiologie, Deutsches Rheuma ForschungsZentrum Berlin
    Z Rheumatol 65:441-6. 2006
    ..Using data from the German Biologics Register RABBIT we investigated: (1) how dosage of INF develops during the first year of treatment in routine care, and (2) how dosage translates into clinical effectiveness...
  35. ncbi request reprint [National database of German arthritis centers. Tool for health services research]
    A Zink
    Forschungsbereich Epidemiologie, Deutsches Rheuma ForschungsZentrum Berlin, Berlin
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:526-32. 2004
    ..Selected results concerning the health care situation in specialized and nonspecialized care, practice variations in rheumatology, and the burden of illness in various diseases are reported...
  36. ncbi request reprint Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials
    Angela Zink
    German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
    Arthritis Rheum 54:3399-407. 2006
    ....
  37. ncbi request reprint [The National Database of the Regional Collaborative Rheumatic Centers as a tool for clinical epidemiology and quality assessment in rheumatology]
    Angela Zink
    Forschungsbereich Epidemiologie, Deutsches Rheuma ForschungsZentrum Berlin
    Z Arztl Fortbild Qualitatssich 97:399-405. 2003
    ..Specific deficits have been identified concerning the provision of occupational therapy services and patient education...
  38. doi request reprint Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers
    Anja Strangfeld
    Epidemiology Unit, German Rheumatism Research Centre, a Leibniz Institute, Chariteplatz 1, D 10117 Berlin, Germany
    Rheumatology (Oxford) 50:146-51. 2011
    ..To evaluate this possible safety signal, a concerted analysis with the national biologics registers in the UK and Sweden was performed...
  39. ncbi request reprint Long-term outcome in patients with juvenile idiopathic arthritis
    Kirsten Minden
    German Rheumatism Research Center, Berlin
    Arthritis Rheum 46:2392-401. 2002
    ..To describe the long-term outcome of juvenile idiopathic arthritis (JIA)...
  40. doi request reprint Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
    Anja Strangfeld
    Epidemiology Unit, German Rheumatism Research Center, Chariteplatz 1, 10117 Berlin, Germany
    JAMA 301:737-44. 2009
    ..The risk of bacterial infection is increased in patients treated with drugs that inhibit tumor necrosis factor alpha (TNF-alpha). Little is known about the reactivation of latent viral infections during treatment with TNF-alpha inhibitors...
  41. doi request reprint The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort
    Martin Rudwaleit
    Charité Medical University Hospital, Campus Benjamin Franklin, and German Rheumatism Research Centre, Berlin, Germany
    Arthritis Rheum 60:717-27. 2009
    ..Moreover, we sought to identify determinants of the development of radiographic sacroiliitis...
  42. ncbi request reprint Health care provision in pediatric rheumatology in Germany--national rheumatologic database
    Kirsten Minden
    Epidemiology Unit, German Rheumatism Research Center Berlin
    J Rheumatol 29:622-8. 2002
    ..To describe the health care provision for children and adolescents with chronic arthritides in Germany in 1998...
  43. ncbi request reprint Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis
    Angela Zink
    German Rheumatism Research Centre, Berlin, Germany
    J Rheumatol 33:86-90. 2006
    ..To compare quality of life and treatment among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) treated by German rheumatologists...
  44. ncbi request reprint Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial
    Hildrun Haibel
    Benjamin Franklin Hospital, Berlin, Germany
    Arthritis Rheum 54:678-81. 2006
  45. pmc Burden and cost of illness in patients with juvenile idiopathic arthritis
    K Minden
    Deutsches Rheuma ForschungsZentrum Berlin, Schumannstr 21 22, 10117 Berlin, Germany
    Ann Rheum Dis 63:836-42. 2004
    ..To estimate the cost of illness in an incidence based cohort of patients with juvenile idiopathic arthritis...
  46. doi request reprint Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 60:3257-62. 2009
    ..The contribution of osteocytes in regulating local bone remodeling in arthritis is unknown. The aim of this study was to investigate the role of osteocytes as contributors to bone remodeling in ankylosing spondylitis (AS)...
  47. ncbi request reprint Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy
    Anja Strangfeld
    German Rheumatism Research Centre, Epidemiology Unit, Chariteplatz 1, D 10117 Berlin, Germany
    Best Pract Res Clin Rheumatol 20:1181-95. 2006
    ..There are atypical signs and symptoms as well as atypical pathogen that should be considered. Patients should be educated about how to avoid infectious complications...
  48. ncbi request reprint Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria
    Martin Rudwaleit
    Charite, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 54:569-78. 2006
    ..In this exploratory study, we sought to evaluate the individual features of IBP and to compose and compare various combinations of features for use as classification and diagnostic criteria...
  49. doi request reprint Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two
    Hildrun Haibel
    Charité Medical University Hospital, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 58:1981-91. 2008
    ..To evaluate the efficacy and safety of the tumor necrosis factor (TNF) antagonist adalimumab in patients with axial spondylarthritis (SpA) without radiographically defined sacroiliitis refractory to conventional treatment...
  50. ncbi request reprint Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis
    Christian Heldt
    Deutsches RheumaForschungs Zentrum, Berlin, Germany
    Arthritis Rheum 48:2779-87. 2003
    ..The aim of this study was to investigate the differential expression of genes encoded within the RA-associated HLA-DR4 superhaplotype and within the neutral DR7 and DR9 superhaplotypes...
  51. ncbi request reprint Biologic therapies in the spondyloarthritis: new opportunities, new challenges
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Curr Opin Rheumatol 15:394-407. 2003
    ..These can be largely prevented by appropriate screening. At it stands now, the benefits of antitumor necrosis factor therapy in ankylosing spondylitis seem to outweigh these shortcomings...
  52. ncbi request reprint Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne Ruhr University, Bochum, Germany
    J Rheumatol 34:510-5. 2007
    ....
  53. pmc Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Res Ther 7:R439-44. 2005
    ..Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one...
  54. ncbi request reprint Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept
    Jan Brandt
    Department of Gastroenterology Rheumatology, Benjamin Franklin Hospital, Free University FU Berlin, Germany
    J Rheumatol 31:531-8. 2004
    ..In this open study we examined the efficacy of the TNF-alpha receptor fusion protein etanercept in patients with uSpA...
  55. ncbi request reprint Employment across chronic inflammatory rheumatic diseases and comparison with the general population
    Wilfried Mau
    Institute for Rehabilitation Medicine, Martin Luther University Halle Wittenberg, Halle, Germany
    J Rheumatol 32:721-8. 2005
    ..To compare labor force participation across chronic inflammatory rheumatic diseases in order to assess the influence of the disease, disease duration, sex, education, and labor market conditions on employment...